Intermediate dose of nonpegylated liposomal doxorubicin combination (R-CMyOP) as first line chemotherapy for frail elderly patients with aggressive lymphoma

Leukemia Research

Volumn 35, Issue 3, 2011, Pages 358-362

  Gimeno, Eva ^a,b   Sánchez González, Blanca ^a   Álvarez Larrán, Alberto ^a   Pedro, Carmen ^a   Abella, Eugenia ^a   Comín, Josep ^a   Saumell, Silvia ^a   García Pallarols, Francesc ^a   Gómez, Miquel ^a   Besses, Carles ^a   Salar, Antonio ^a  

^a HOSPITAL DEL MAR   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Aggressive lymphoma; Chemotherapy; Elderly; Frail population; Nonpegylated liposomal doxorubicin

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; AGGRESSIVE LYMPHOMA; ANEMIA; ARTICLE; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; FRAIL ELDERLY; GRANULOCYTOPENIA; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; INFECTION; LYMPHOMA; MALE; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; SIDE EFFECT; THROMBOCYTOPENIA;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PREDNISONE; PROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; VINCRISTINE;

EID: 79952101955     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.07.024     Document Type: Article

References (50)

1. Pedersen N.T., Bendix-Hansen K., Johansen P. Non-Hodgkin's lymphoma subtypes over time in an unselected population of 646 patients: a study of clinico-pathological data and incidence based on a review using the REAL-classification. Leuk Lymphoma 2000, 39:531-541.
2. Cartwright R., Brincker H., Carli P.M., Clayden D., Coebergh J.W., Jack A., et al. The rise in incidence of lymphomas in Europe 1985-1992. Eur J Cancer 1999, 35:627-633.
3. Muller A., Ihorst G., Mertelsmann R., Engelhardt M. Epidemiology of non-Hodgkin's lymphoma (NHL): trends, geographic distribution and etiology. Ann Haematol 2005, 84:1-12.
4. Coiffier B., Lepade E., Briere J., et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002, 346:235-242.
5. Armitage J.O., Potter J.F. Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly: increased complications with advancing age. J Am Geriatr Soc 1984, 32:269-273.
6. Gianni L., Herman E.H., Lipshultz S.E., Minotti G., Sarvazyan N., Sawyer D.B. Anthracycline cardiotoxicity: from bench to bedside. J Clin Oncol 2008, 26(22):3777-3784.
7. Doyle J.J., Neugut A.I., Jacobson J.S., Grann V.R., Hershman D.L. Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. J Clin Oncol 2005, 23(34):8597-8605.
8. Limat S., Demesmay K., Voillat L., Bernard Y., Deconinck E., Brion A., Woronoff-Lemsi M.C., et al. Early cardiotoxicity of the CHOP regimen in aggressive non-Hodgkin's lymphoma. Ann Oncol 2003, 14(2):277-281.
9. Hequet O., Le Q.H., Moullet I., Pauli E., Salles G., Espinouse D., et al. Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults. J Clin Oncol 2004, 22(10):1864-1871.
10. Hershman D.L., McBride R.B., Eisenberger A., Tsai W.Y., Grann V.R., Jacobson J.S. Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma. J Clin Oncol 2008, 26(19):3159-3165.
11. Braunwald E. Biomarkers in heart failure. N Engl J Med 2008, 358:2148-2159.
12. Lemos J., McGuire D., Drazner M. B-type natriuretic peptide in cardiovascular disease. The Lancet 2003, 362:316-322.
13. Lemos J., Morrow D.A., Bentley J.H., Omland T., Sabatine M.S., McCabe C.H., et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001, 345:1014-1021.
14. Baughman K.L. B-type natriuretic peptide in the diagnosis of heart failure. N Engl J Med 2002, 347:158-159.
15. Wang T.J., Gona P., Larson M.G., Tofler G.H., Levy D., Newton-Cheh C., et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 2006, 355:2631-2639.
16. Wang T.J., Larson M.G., Levy D., Benjamin E.J., Leip E.P., Omland T., et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004, 350:655-663.
17. Kragelund C., Gronning B., Kober L., Hildebrandt P., Steffensen R. N-terminal pro-B-type natriuretic peptide and longterm mortality in stable coronary heart disease. N Engl J Med 2005, 352:666-675.
18. Berglund L., Sundström J., Ingelsson E., Basu S., Larsson A., Venge P., et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 2008, 358:2107-2116.
19. Kistorp C., Raymond I., Pedersen F., Gustafsson F., Faber J., Hildebrandt P. N-terminal pro-brain natriuretic peptide. C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA 2005, 293:1609-1616.
20. Knight E.L., Kiely D.K., Fish L.C., Marcantonio E.R., Minaker K.L. Atrial natriuretic peptide level contributes to a model of future mortality in the oldest old. J Am Geriatr Soc 1998, 46:453-457.
21. Palladini G., Campana C., Klersy C., Balduini A., Vadacca G., Perfetti V., et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 2003, 107:2440-2445.
22. Dispenzieri A., Kyle R.A., Gertz M.A., Therneau T.M., Miller W.L., Chandrasekaran K., et al. Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet 2003, 361:1787-1789.
23. Dispenzieri A., Gertz M.A., Kyle R.A., Lacy M.Q., Burritt M.F., Therneau T.M., et al. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplant. Blood 2004, 104:1881-1887.
24. Suzuki T., Hayashi D., Yamazaki T., Mizuno T., Kanda Y., Komuro I., et al. Elevated B-type natriuretic peptide levels after anthracycline administration. Am Heart J 1998, 136:362-363.
25. Cil T., Kaplan A.M., Altintas A., Akin A.M., Alan S., Isikdogan A. Use of N-terminal pro-brain natriuretic peptide to assess left ventricular function after adjuvant doxorubicin therapy in early breast cancer patients: a prospective series. Clin Drug Invest 2009, 29(2):131-137.
26. Sonneveld P., de Ridder M., van der Lelie H., Nieuwenhuis K., Schouten H., Mulder A., et al. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. J Clin Oncol 1995, 13:2530-2539.
27. Meyer R.M., Browman G.P., Samosh M.L., Benger A.M., Bryant-Lukosius D., Wilson W.E., et al. Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin's lymphoma. J Clin Oncol 1995, 13:2386-2393.
28. Grogan T.M., Mize E.M., Glick J.H., Coltman C.A., Miller T.P. Comparison of standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993, 328:1002-1006.
29. Trümper L., Kloess M., Schmits R., Feller A.C., Rübe C., Rudolph C., et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-BS trial of the DSHNHL. Blood 2004, 104:634-641.
30. Swain S.M., Whaley F.S., Gerber M.C., Weisberg S., York M., Spicer D., et al. Cardioprotection with dexrazoxane for doxorubicin containing therapy in advanced breast cancer. J Clin Oncol 1997, 15:1318-1332.
31. Neri N., Castañeda C., Talavera A., Huerta-Guzmán J., González M. Pegylated liposomal doxorubicin in combination chemotherapy in the treatment of previously untreated aggressive diffuse large-B-cell lymphoma. Med Oncol 2002, 19:55-58.
32. Martino R., Perea G., Caballero M.D., Mateos M.V., Ribera J.M., de Oteyza J.P., et al. Cyclophosphamide, pegylated liposomal doxorrubicin (Caelix), vincristine and prednisone (CCOP) in elderly patients with diffuse large-B-cell lymphoma: results from a prospective phase II study. Haematologica 2002, 87:822-827.
33. Tsavaris N., Kosmas C., Vadiaka M., Giannouli S., Siakantaris M.P., Vassilakopoulos T., et al. Pegylated liposomal doxorubicin in the CHOP regimen for older patients with aggressive (stages III/IV) non-Hodgkin's lymphoma. Anticancer Res 2002, 22:1845-1848.
34. Zaja F., Tomadini V., Zaccaria A., Lenoci M., Battista M., Molinari A.L., et al. CHOP-rituximab with pegylated liposomal doxorrubicin for the treatment of elderly patients with diffuse large B-cell lymphoma. Leuk Lymphoma 2006, 47(10):2174-2180.
35. Mayer L.D., Bally M.B., Cullis P.R., Wilson S.L., Emerman J.T. Comparision of free and liposome-encapsulated doxorubicin tumor drug uptake and antitumor efficacy in the SC115 murine mammary tumor. Cancer Lett 1990, 53:183-190.
36. Cowens J.W., Creaven P.J., Greco W.R., Brenner D.E., Tung Y., Ostro M., et al. Initial clinical (phase I) trial of myocet (doxorubicin encapsulated in liposomes). Cancer Res 1993, 53:2796-2802.
37. Batist G., Ramakrishnan G., Rao C.S., Chandrasekharan A., Gutheil J., Guthrie T., et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide in randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 2001, 19:1444-1454.
38. Welles L., Chow S.C., Bhamra R., Chaikin P. Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer. Anticancer Drugs 2003, 14(March (3)):239-246.
39. Mlineritsch B., Schabel-Moser R., Andel J., Fridrik M., Moik M., Mayer P., et al. Multicenter phase II study of pegylated liposomal doxorubicin in combination with vinorelbine as first-line treatment in elderly patients with metastatic breast cancer. Onkologie 2009, 32(1-2):18-24.
40. Smith T.J., Khatcheressian J., Lyman G.H., Ozer H., Armitage J.O., Balducci L., et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guidelines. J Clin Oncol 2006, 24:3187-3285.
41. Lister T.A., Crowther D., Sutcliffe S.B., Glatstein E., Canellos G.P., Young R.C., et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989, 7:1630-1636.
42. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993, 329:987-994.
43. Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R.A. New method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40:373-383.
44. Cheson B.D., Pfistner B., Juweid M.E., Gascoyne R.D., Specht L., Horning S.J., et al. International harmonization project on lymphoma. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI sponsored International Working Group. J Clin Oncol 2007, 25:579-586.
45. National Cancer Institute Common toxicity criteria, NCI-CTC version 2.0 January 30, 1998, http://ctep.cancer.gov/reporting/CTC-3.html.
46. Salar, Sanchez-Gonzalez B., Alvarez-Larran A., Comin J., Gonzalez J.R., Gimeno E., et al. NT-ProBNP prediction of major chemotherapy-related toxicity and death in lymphoma patients. J Clin Oncol 2009, 27:15s. [suppl; abstr. 9569].
47. Rigacci L., Mappa S., Nassi L., Alterini R., Carrai V., Bernardi F., et al. Liposome-encapsulated doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab in patients with lymphoma and concurrent cardiac diseases or pre-treated with anthracyclines. Hematol Oncol 2007, 25:198-203.
48. Visani G., Ferrara F., Alesiani F., Ronconi S., Catarini M., D'adamo F., et al. R-COMP 21 for frail elderly patients with aggressive B-cell non-Hodgkin lymphoma: a pilot study. Leuk Lymphoma 2008, 49(6):1081-1086.
49. Heintel D., Skrabs C., Hauswirth A., Eigenberger K., Einberger C., Raderer M., et al. Nonpegylated liposomal doxorubicin is highly active in patients with B and T/NK cell lymphomas with cardiac comorbidity or higher age. Ann Hematol 2009, 89(2):163-169.
50. Luminari S., Montanini A., Caballero D., Bologna S., Notter M., Dyer M.J., et al. Nonpegylated liposomal doxorubicin (Myocet®) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): results from the phase II EURO18 trial. Ann Oncol 2010, 21(7):1492-1499.